Clinical Considerations in Evidence-based Management of GIST

Program Goals

GIST Current Treatment Paradigm

What is GIST?

What Causes GIST?

GIST: Treatment

Imatinib: Clinical Trial Results

Imatinib: Early Stage GIST

Resistance to Imatinib

Sunitinib

Regorafenib

Wild-type GIST (“Pediatric GIST”)

GIST Therapy: What Next?

Drug Interactions: Comparison

GIST Adverse Effects and Management Strategies

GIST: Optimizing Patient Outcomes

Hypertension

Hypertension (cont)

Other Cardiovascular Risks

Hand Foot Skin Reaction (HFSR)

Hand Foot Skin Reaction (HFSR) (cont)

Other Dermatologic Toxicities

Other Dermatologic Toxicities (cont)

Fatigue

Oral Toxicity

Diarrhea

Nausea

Laboratory Value Abnormalities

Unique to Imatinib

Unique to Regorafenib

Targeted Therapies for GIST: Comparison of Adverse Events (Grades 3-4)

GIST Encouraging Adherence to Therapy

Adherence to Therapy

Factors Associated With Non-Adherence to Oral Anticancer Therapy

Known Factors Associated With Non-Adherence to Oral Anticancer Therapy

Factors Associated With Non-Adherence to Oral Anticancer Therapy (cont)

Adherence With TKIs

Adherence With TKIs (cont)

Consider Over-adherence

Role of Nurse and Clinical Pharmacist

Role of Nurse and Clinical Pharmacist (cont)

Abbreviations

References (cont)

Abbreviations (cont)

References

References (cont)

References (cont)